AIM ImmunoTech

AIM ImmunoTech has agreed with Sterling Pharma Solutions to produce additional batches of the polynucleotides PolyI and Poly C12U in Dudley for use as polymer precursors for the drug Ampligen. The cost is about $1.5 million, payable over 12 months, and the materials are intended for ongoing and planned clinical trials, including a potential Phase 3 study against metastatic pancreatic cancer. The company also reports the early completion of patient recruitment for the Phase 2 DURIPANC study and discloses several financing transactions to bolster liquidity, including a direct offering and private placements. » Más en de.investing.com

On May 8, AIM ImmunoTech received roughly $3.6 million gross under an agreement for incentivized warrant exercises. Holders of class A through F warrants exercised 7,451,920 warrants at a reduced exercise price of $0.48; in exchange the company issued new class H warrants for up to 14,903,840 common shares at $0.60. The company also reported recent capital inflows of about $4.2 million from an agreement with accredited investors and roughly $1.8 million from a rights offering, and it removed the previous $3 million cap on at‑the‑market sales. AIM plans to use the proceeds for working capital and to advance its clinical development, including a planned phase 3 study of Ampligen in pancreatic cancer in collaboration with PPD/Thermo Fisher. Market capitalization is about $2.51 million and the stock is trading near its 52‑week low. » Más en de.investing.com

AIM ImmunoTech amended its placement agreement with Maxim Group and removed the previous $3 million cap on at-the-market sales, allowing more common shares to be sold under the S-3 registration going forward. Maxim remains the exclusive placement agent, and the company filed a prospectus supplement to increase the shares offered. The move comes amid heavy financial pressure: stock around $0.52, market capitalization roughly $4.2 million, and negative free cash flow of $12.9 million. AIM also completed a rights offering of about $1.8 million, creating a new class of series G preferred shares and 3,684,000 class G warrants. » Más en de.investing.com